LakeShore Biopharma Co (LakeShore Biopharma Co) Debt-to-Asset : 0.34 (As of Sep. 2023)

View and export this data going back to 2023. Start your Free Trial

What is LakeShore Biopharma Co Debt-to-Asset?

LakeShore Biopharma Co's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $25.73 Mil. LakeShore Biopharma Co's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Sep. 2023 was $50.21 Mil. LakeShore Biopharma Co's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Sep. 2023 was $220.79 Mil. LakeShore Biopharma Co's debt to asset for the quarter that ended in Sep. 2023 was 0.34.

LakeShore Biopharma Co Debt-to-Asset Historical Data

The historical data trend for LakeShore Biopharma Co's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

LakeShore Biopharma Co Debt-to-Asset Chart

LakeShore Biopharma Co Annual Data

Trend

Mar21

Mar22

Mar23

Debt-to-Asset

0.02

0.26

0.29

LakeShore Biopharma Co Semi-Annual Data
	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Debt-to-Asset	Get a 7-Day Free Trial			-	0.26	0.30	0.29	0.34

Competitive Comparison of LakeShore Biopharma Co's Debt-to-Asset

For the Biotechnology subindustry, LakeShore Biopharma Co's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

LakeShore Biopharma Co's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, LakeShore Biopharma Co's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where LakeShore Biopharma Co's Debt-to-Asset falls into.

LakeShore Biopharma Co Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

LakeShore Biopharma Co's Debt-to-Asset for the fiscal year that ended in Mar. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(28.805	+	43.556)	/	249.569
	=	0.29

LakeShore Biopharma Co's Debt-to-Asset for the quarter that ended in Sep. 2023 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(25.729	+	50.21)	/	220.787
	=	0.34

LakeShore Biopharma Co (NAS:LSB) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

LakeShore Biopharma Co Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of LakeShore Biopharma Co's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

LakeShore Biopharma Co (LakeShore Biopharma Co) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » LakeShore Biopharma Co Ltd (NAS:LSB) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

H6Z:Germany

Address

38 Yongda Road, Building No. 2, Daxing Biomedical Industry Park, Daxing District, Beijing, CHN, 102629

Website

https://www.yishengbio.com

YS Biopharma Co Ltd is principally engaged in the research, development, manufacturing and sale of vaccines and therapeutic biologics. It developed a PIKA immunomodulating technology platform and a series of product candidates targeting rabies, hepatitis B, influenza and other indications. It is also conducting the production and sale of YSJA, a rabies vaccine, the first aluminium-free lyophilized rabies vaccine that was launched in China. It has one operating segment, which is the development, production, marketing and sale of biopharmaceutical products.